An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)

Conditions

• Ankylosing Spondylitis

Interventions

• DRUG: adalimumab (Humira)

Sponsor

Abbott